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Most psychotherapies for depression have been developed in high-income Western countries of North America, Europe and Australia. A grow-
ing number of randomized trials have examined the effects of these treatments in non-Western countries. We conducted a meta-analysis of
these studies to examine whether these psychotherapies are effective and to compare their effects between studies from Western and non-
Western countries. We conducted systematic searches in bibliographical databases and included 253 randomized controlled trials, of which 32
were conducted in non-Western countries. The effects of psychotherapies in non-Western countries were large (g51.10; 95% CI: 0.91-1.30), with
high heterogeneity (I2590; 95% CI: 87-92). After adjustment for publication bias, the effect size dropped to g50.73 (95% CI: 0.51-0.96). Sub-
group analyses did not indicate that adaptation to the local situation was associated with the effect size. Comparisons with the studies in
Western countries showed that the effects of the therapies were significantly larger in non-Western countries, also after adjusting for character-
istics of the participants, the treatments and the studies. These larger effect sizes in non-Western countries may reflect true differences indicat-
ing that therapies are indeed more effective; or may be explained by the care-as-usual control conditions in non-Western countries, often
indicating that no care was available; or may be the result of the relative low quality of many trials in the field. This study suggests that psy-
chotherapies that were developed in Western countries may or may not be more effective in non-Western countries, but they are probably no
less effective and can therefore also be used in these latter countries.
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(World Psychiatry 2018;17:90–101)
Depression and other common mental disorders are highly
prevalent, with almost one in five people worldwide affect-
ed1,2. They have a considerable impact on the lives of patients
and their families, and are associated with huge economic and
societal costs3. The disability associated with these disorders
results in a loss of more than one million healthy life years,
which makes mental disorders the leading cause of years lived
with disability worldwide4. The economic costs, in terms of
production losses and health and social care expenditures,
have been estimated at US$2.5 trillion in 2010 worldwide5-7,
and these costs are expected to grow to US$6.0 trillion by
20308.
Several evidence-based pharmacotherapies and psychother-
apies are available for depression. However, most people with a
depressive disorder do not receive treatment, especially in low-
and middle-income countries, where only between 7 and 21%
of patients are treated5. If patients get treatment, this typically
consists of pharmacotherapy, while the majority of patients
prefer psychotherapies9.
Several psychotherapies, such as cognitive behavior ther-
apy, interpersonal psychotherapy, problem-solving and behav-
ioral activation, have been developed for the treatment of depres-
sion10. Since the 1970s, several hundreds of randomized trials
have shown that these interventions are effective11-14, al-
though their effects are modest and have been overestimated
because of the low quality of many trials15 and publication
bias16,17. The effects of psychotherapies have been found to be
comparable to those of pharmacotherapy18, and probably last
longer19.
Most psychotherapies have been developed in high-income
Western countries in North America, Europe and Australia,
and the vast majority of the more than 450 randomized trials
which have examined their effects20 have been conducted in
those countries. It is therefore not well known whether these
therapies are also effective in low- and middle-income coun-
tries.
In recent years, a growing number of randomized trials
have examined the effects of psychotherapies for depression
in countries outside of North America, Europe and Australia.
The goal of the present meta-analysis is to examine whether
these psychotherapies are also effective in non-Western coun-
tries and to compare their effects with those in Western coun-
tries. This also gives the opportunity to examine whether the
effects of psychotherapies are associated with the income of
the country and the region where the trial was conducted.
METHODS
Identification and selection of studies
We used an existing database of studies on psychotherapies
for depression. This database has been described in detail else-
where20, has been used in a series of earlier published meta-
analyses21, and is continuously updated. For this database we
searched four major bibliographical sources (PubMed, Psyc-
INFO, Embase and the Cochrane Library) by combining terms
(both index terms and text words) indicative of depression and
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psychotherapies, with filters for randomized controlled trials.
We also checked the references of earlier meta-analyses.
Because this database was not developed specifically to
include studies from non-Western countries, we examined the
list produced by the Effective Practice and Organization of
Care (EPOC) Group (a Cochrane review group), which con-
tains a collection of databases, websites and journals relevant
to low- and middle-income countries. We selected databases
that were freely available, could be searched in English, and
had a working web address. The following databases were
searched with adapted search strings: the International Initia-
tive for Impact Evaluation (3ie); the British Library for Devel-
opment Studies; the Eldis; the World Health Organization
(WHO)’s Global Index Medicus; the Latin-American and Carib-
bean System on Health Sciences Information (LILACS); the
Indice Bibliografico Espa~nol de Ciencias de la Salud (IBECS);
the AfricaBib; the IndMed; the KoreaMed; and African Journals
Online. The search was made in November 2016.
All records were screened by two independent researchers
and all papers that could possibly meet inclusion criteria accord-
ing to one of the researchers were retrieved as full text. The
decision to include or exclude a study was also done by the
two independent researchers, and disagreements were solved
through discussion.
We included papers reporting on a randomized trial in
which a psychotherapy for adult depression was compared
with a control group (waiting list, care-as-usual, placebo, other
inactive treatment) in a non-Western country (not located in
North America, Europe or Australia).
Depression could be established by a diagnostic interview
or a score above a cut-off on a self-report scale. Psychothera-
pies were defined as interventions with a primary focus on
language-based communication between a patient and a ther-
apist, or as bibliotherapy supported by a therapist22. The ther-
apies could be delivered individually, in groups, or as guided
self-help by professionals or para-professionals. Comorbid
mental or somatic disorders were not used as an exclusion cri-
terion. Studies on inpatients were excluded. We also excluded
maintenance studies aimed at people who had already recov-
ered or partly recovered after an earlier treatment.
In addition to the main analyses of the studies conducted in
non-Western countries, we also compared treatment effect
sizes in the trials conducted in non-Western countries with
those conducted in Western countries. For this comparison,
we selected from our database trials on psychotherapies for
depression that were conducted in Western countries and in
which psychotherapy was compared with a control condition,
with the same inclusion and exclusion criteria as for the stud-
ies in non-Western countries.
Quality assessment and data extraction
We assessed the quality of included studies using four crite-
ria of the “Risk of bias” assessment tool, developed by the
Cochrane Collaboration23. This tool assesses possible sources
of bias in randomized trials, including the adequate genera-
tion of allocation sequence; the concealment of allocation to
conditions; the prevention of knowledge of the allocated inter-
vention (masking of assessors); and dealing with incomplete
outcome data (this was assessed as positive when intention-
to-treat analyses were conducted, meaning that all random-
ized patients were included in the analyses). Assessment of the
quality of the included studies was conducted by two indepen-
dent researchers, and disagreements were solved through discus-
sion.
We also coded participant characteristics (depressive disor-
der or scoring high on a self-rating scale; recruitment method;
target group); characteristics of the psychotherapies (treatment
format; number of sessions); and general characteristics of the
studies (type of control group; country where the study was
conducted).
We rated whether the intervention was adapted to the local
setting and population. We considered an intervention not
adapted when the authors did not mention adaptation and
when the procedures described were comparable to those
found in therapies developed in Western countries. An inter-
vention was considered as adapted when it was explicitly men-
tioned that it was adapted to the local situation. We consider-
ed an intervention also as “adapted” when it was developed in
a non-Western country and was based on models or theories
from non-Western countries. We also considered an interven-
tion as “not adapted” when Western manuals were just trans-
lated into the national language.
In order to examine whether the effects of psychotherapy
were associated with the per capita income, we recorded the
gross national income (GNI) based on purchasing power par-
ity (PPP) per capita in international dollars for each of the
countries where a trial was conducted, using data from the
World Bank (http://data.worldbank.org). We categorized the
countries into low-, lower-middle, upper-middle and high-
income ones according to the definition of the World Bank. We
also used the six World Bank regions to categorize where the
studies were conducted (East Asia and Pacific, Europe and
Central Asia, Latin America and the Caribbean, Middle East
and North Africa, South Asia, and Sub-Saharan Africa).
Primary outcome
For each comparison between a psychotherapy and a con-
trol condition, the effect size indicating the difference between
the two groups at post-test was calculated (Hedges’ g). Effect
sizes of 0.8 can be assumed to be large, while effect sizes of 0.5
are moderate, and effect sizes of 0.2 are small24. Effect sizes
were calculated by subtracting (at post-test) the average score
of the psychotherapy group from the average score of the con-
trol group, and dividing the result by the pooled standard devi-
ation. Because some studies had relatively small sample sizes,
we corrected the effect size for small sample bias25. If means
and standard deviations were not reported, we used the proce-
dures of the Comprehensive Meta-Analysis software (see
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below) to calculate the effect size using dichotomous out-
comes; and if these were not available either, we used other
statistics (such as t or p value) to calculate the effect size.
In order to calculate effect sizes, we used all measures
examining depressive symptoms, such as the Beck Depression
Inventory (BDI-I or BDI-II)26,27 or the Hamilton Rating Scale
for Depression (HAMD-17)28.
Meta-analyses
To calculate pooled mean effect sizes, we used the computer
program Comprehensive Meta-Analysis (version 3.3070). Because
we expected considerable heterogeneity among the studies, we
employed a random effects pooling model in all analyses.
Numbers-needed-to-be-treated (NNT) were calculated using
the formulae provided by Furukawa29, in which the control
group’s event rate was set at a conservative 19% (based on the
pooled response rate of 50% reduction of symptoms across trials
in psychotherapies for depression)30. As a test of homogeneity
of effect sizes, we calculated the I2 statistic, which is an indicator
of heterogeneity in percentages. A value of 0% indicates no
observed heterogeneity, and larger values indicate increasing
heterogeneity, with 25% as low, 50% as moderate, and 75% as
high heterogeneity31. We calculated 95% confidence intervals
(CIs) around I2 using the non-central chi-squared-based ap-
proach within the heterogi module for Stata32,33. We conducted
sensitivity analyses excluding potential outliers. These were
defined as studies in which the 95% CI of the effect size did not
overlap with the 95% CI of the pooled effect size.
We conducted subgroup analyses according to the mixed ef-
fects model, in which studies within subgroups are pooled with
the random effects model, while tests for significant differences
between subgroups are conducted with the fixed effects model.
For continuous variables, we used meta-regression analyses to
test whether there was a significant relationship between the
continuous variable and effect size, as indicated by a z value
and an associated p value. Multivariate meta-regression anal-
Figure 1 PRISMA flow chart
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Table 1 Selected characteristics of randomized trials comparing psychotherapies for adult depression to control groups in non-
Western countries
Study Conditions N patients Format Cultural adaptation N sessions Country Risk of bias*
Bolton et al35 IPT 139 Group Adapted 16 Uganda 1 – SR 1
CAU 145
Chan et al36 CBT 17 Individual Not adapted 10 China – 1 1 –
MBCT 17 Individual Non-Western 10
WL 16
Chan et al37 Other 14 Individual Non-Western 5 China 1 – SR 1
CAU 12
Chen et al38 SUP 30 Group Not adapted 4 Taiwan – – SR –
CAU 30
Chiang et al39 CBT 30 Group Not adapted 12 Taiwan 1 1 1 –
CAU 32
Cho et al40 CBT 12 Individual Not adapted 9 Korea – – SR –
CAU 10
Duarte et al41 CBT 41 Group Not adapted 12 Brazil – 1 SR –
CAU 44
Faramarzi et al42 CBT 29 Group Not adapted 10 Iran – – SR –
CAU 30
Furukawa et al43 CBT 58 Individual Adapted 8 Japan 1 1 SR 1
WL 60
Garcıa-Pe~na et al44 CBT 41 Group Not adapted 12 Mexico 1 – SR –
CAU 40
Hamdan-Mansour et al45 CBT 44 Group Adapted 10 Jordan – 1 SR –
CAU 36
Hou et al46 CBT 104 Individual Not adapted 19 China – – SR –
CAU 109
Huang et al47 CBT 31 Group Not adapted 12 Taiwan – – SR –
CAU 30
Jiang et al48 Other 257 Individual Not adapted – China 1 – SR –
CAU 514
Leung et al49 CBT 47 Group Adapted 6 China – – SR 1
CAU 50
Liu et al50 CBT 27 Guided self-help Not adapted 10 Taiwan – – SR –
WL 25
Mukhtar51 CBT 58 Group Adapted 8 Malaysia – – SR –
WL 55
Naeem et al52 CBT 94 Guided self-help Adapted 7 Pakistan 1 – SR –
CAU 89
Nakimuli-Mpungu et al53 SUP 57 Group Adapted 8 Uganda 1 1 SR 1
Other 52
Ng et al54 Other 14 Individual Not adapted 5 Singapore – – SR –
CAU 12
Ngai et al55 CBT 197 Other Adapted 5 China 1 1 SR 1
CAU 200
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yses, with the effect size as the dependent variable, were con-
ducted through Comprehensive Meta-Analysis.
We tested for publication bias by inspecting the funnel plot
on primary outcome measures and by Duval and Tweedie’s
trim and fill procedure34, which yields an estimate of the effect
size after the publication bias has been taken into account (as
implemented in Comprehensive Meta-Analysis). We also con-
ducted Egger’s test of the intercept to quantify the bias cap-
tured by the funnel plot and to test whether it was significant.
RESULTS
Selection and inclusion of studies
After examining a total of 16,908 abstracts (13,774 after
removal of duplicates), we retrieved 1,888 full-text papers for
further consideration. We excluded 1,635 of the retrieved
papers. The PRISMA flow chart describing the inclusion pro-
cess, with the reasons for exclusion, is presented in Figure 1.
A total of 32 studies conducted in non-Western countries
(with 35 comparisons between a psychotherapy and a control
condition) met inclusion criteria for this meta-analysis (Table 1).
Another 221 studies (with 297 comparisons between a treatment
and a control group) on psychotherapies in Western countries
were included (for the comparison of effect sizes in Western ver-
sus non-Western countries). This makes a total of 253 studies
that were included in the analyses.
Characteristics of included studies
In the 32 included studies conducted in Non-Western coun-
tries, a total of 4,607 patients participated (2,222 for therapy
conditions and 2,385 for control conditions). Participants were
Table 1 Selected characteristics of randomized trials comparing psychotherapies for adult depression to control groups in non-
Western countries (continued)
Study Conditions N patients Format Cultural adaptation N sessions Country Risk of bias*
Omidi et al56 CBT 30 Group Not adapted 8 Iran – – SR –
MBCT 30 Group Not adapted 8
CAU 30
Petersen et al57 IPT 17 Group Adapted 8 South Africa 1 – SR –
CAU 17
Qiu et al58 CBT 31 Group Not adapted 10 China 1 1 1 1
WL 31
Rahman et al59 CBT 418 Individual Adapted 16 Pakistan 1 1 1 –
Other 400
Songprakun & McCann60 CBT 26 Guided self-help Not adapted 8 Thailand 1 1 1 –
CAU 28
Sreevani et al61 Other 15 Group Non-Western 4 India 1 – SR –
CAU 15
Teichman et al62 CMT 15 Individual Not adapted 13 Israel – – SR –
CBT 15 Individual Not adapted 13
WL 15
Vitriol et al63 DYN 44 Individual Not adapted 12 Chile – – 1 1
CAU 43
Wong64 CBT 48 Group Adapted 10 China – 1 SR 1
WL 40
Wong65 CBT 163 Group Adapted 10 China – 1 SR –
WL 159
Zu et al66 CBT 12 Individual Not adapted 20 China 1 – 1 –
CAU 16
CAU – care as usual, CBT – cognitive behavior therapy, CMT – cognitive marital therapy, CT – cognitive therapy, DR – psychodrama, DYN – psychodynamic
therapy, IPT – interpersonal psychotherapy, MBCT – mindfulness based cognitive therapy, SUP – non-directive supportive therapy
*A positive (1) or negative (2) sign is given for four quality criteria: allocation sequence, concealment of allocation to conditions, blinding of assessors, and
intention-to-treat analyses; SR indicates that only self-report measures (and no assessor) were used
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recruited through announcements in local newspapers and
other media (four studies), referrals from health services (11
studies), or other strategies such as screening at general medi-
cal services (17 studies).
In 25 of the 35 comparisons between a treatment and a con-
trol condition, cognitive behavior therapy was used as the
intervention. Two studies used interpersonal psychotherapy,
one used psychodynamic therapy, one used non-directive sup-
portive therapy, and the remaining six used another type of
treatment. Of these treatments, 12 were culturally adapted, 20
were not culturally adapted, and three were non-Western treat-
ments. Eighteen comparisons used a group treatment format,
13 utilized individual treatment, and three used a guided self-
help treatment format. The number of treatment sessions
ranged from four to 20. Eight studies used a waiting list as con-
trol group, 22 studies used care-as-usual, and two used another
control group.
Nineteen studies were conducted in East Asia, three in
South Asia, three in Latin America and the Caribbean, four in
the Middle East and North Africa, and three in Sub-Saharan
Africa. The gross national income of the countries ranged from
low/low-medium (250 US$) to high (54,580 US$).
Effects of psychotherapies in non-Western countries
The overall effect in the 35 comparisons between psycho-
therapies and control groups was g51.10 (95% CI: 0.91-1.30),
which corresponds with a NNT of 2.51. Heterogeneity was very
high (I2590; 95% CI: 87-92). Effect sizes and 95% confidence
intervals of each study are presented in the forest plot in Figure
2. The results of these main analyses are presented in Table 2.
Considering only the outcomes measured with the HAM-D-
17, the mean effect size was g51.38 (95% CI: 0.66-2.09; n57;
Figure 2 Forest plot of effect sizes from randomized controlled trials of psychotherapies for depression in Non-Western countries. CBT – cog-
nitive behavior therapy, MBCT – mindfulness based cognitive therapy, DR – psychodrama, CMT – cognitive marital therapy
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NNT51.99; I2593; 95% CI: 89-95). For the BDI-I, it was g51.33
(95% CI: 0.54-2.12; n59; NNT52.06; I2593; 95% CI: 90-95); for
the BDI-II, it was g51.37 (95% CI: 0.76-1.97; n57; NNT52.01;
I2591; 95% CI: 85-94).
Nine studies were potential outliers39,47,49-51,53,55,58,59. After
exclusion of these studies, the effects dropped to g50.95 (95%
CI: 0.82-1.08; NNT52.95). Heterogeneity was still moderate
(I2555; 95% CI: 23-70). There were three potential outliers
with extremely high effect sizes (g>2.0)39,51,58. The pooled
effect size after excluding these extreme outliers was g50.87
(95% CI: 0.73-1.06; I2578; 95% CI: 69-83).
In this meta-analysis, we included three studies in which
two psychological treatments were compared with the same
control group. This means that multiple comparisons were
included in the same analysis, which may have resulted in an
artificial reduction of heterogeneity and may have affected the
pooled effect size. We examined the possible effects of this by
conducting an analysis in which we included only one effect
Table 2 Psychotherapies for adult depression in non-Western countries compared with control conditions
N g 95% CI I2 95% CI p NNT
All comparisons 35 1.10 0.91-1.30 90 87-92 2.51
One effect size per study (highest only) 32 1.11 0.90-1.32 90 88-92 2.49
One effect size per study (lowest only) 32 1.06 0.85-1.27 90 88-92 2.62
Outliers excluded 26 0.95 0.82-1.08 55 23-70 2.95
Extreme positive outliers excluded 32 0.87 0.73-1.06 78 69-83 3.26
Only HAM-D 7 1.38 0.66-2.09 93 89-95 1.99
Only BDI-I 9 1.33 0.54-2.12 93 90-95 2.06
Only BDI-II 7 1.37 0.76-1.97 91 85-94 2.01
Adjusted for publication bias (9 imputed) 44 0.73 0.51-0.96 93 92-94 3.98
Subgroup analyses
Region East Asia 17 0.83 0.64-1.02 77 61-84 0.55 3.44
Middle East and North Africa 6 1.17 0.69-1.65 74 18-87 2.35
South Asia 3 0.86 0.47-1.25 77 0-91 3.30
Other 6 0.73 0.30-1.16 85 64-91 3.98
Income level of country High 8 0.86 0.48-1.23 71 24-84 0.95 3.30
Upper middle 18 0.89 0.71-1.08 77 63-84 3.18
Low/lower middle 6 0.83 0.44-1.22 88 76-93 3.44
Risk of bias 0-1 (high) 10 1.20 0.84-1.56 73 42-84 <0.001 2.29
2-3 16 0.87 0.70-1.03 61 22-76 3.26
4 (low) 6 0.51 0.34-0.69 60 0-82 6.01
Control group Care as usual 22 0.97 0.78-1.16 80 71-86 0.02 2.88
Waiting list/other 10 0.65 0.45-0.85 61 0-79 4.55
Target group Adults 15 0.95 0.74-1.16 65 32-79 0.16 2.95
Perinatal depression 7 0.67 0.44-0.90 84 67-91 4.39
Other 10 0.97 0.60-1.35 80 60-88 2.88
Diagnosis Depressive disorder 21 0.91 0.74-1.09 74 57-82 0.48 3.02
Cut-off on scale 11 0.80 0.53-1.07 84 72-89 3.58
Adaptation Yes 14 0.74 0.56-0.93 80 65-87 0.06 3.92
No 18 0.99 0.78-1.19 68 42-79 2.82
Type of therapy CBT 22 0.85 0.69-1.01 75 60-82 0.71 3.35
Other 10 0.91 0.63-1.19 76 50-86 3.10
Format of therapy Individual 12 0.89 0.68-1.10 63 17-79 0.28 3.18
Group 15 0.94 0.69-1.20 81 68-87 2.99
Other 5 0.64 0.35-0.94 78 27-89 4.63
BDI – Beck Depression Inventory, HAM-D – Hamilton Rating Scale for Depression, NNT – numbers-needed-to-be-treated, CBT – cognitive behavior therapy
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size per study. First, we included only the comparisons with
the largest effect size from these studies and then we included
only the smallest effect sizes. As can be seen from Table 2, the
resulting effect sizes were almost the same as in the overall
analyses. Heterogeneity was still very high in these analyses.
Visual inspection of the funnel plot, as well as Duval and
Tweedie’s trim and fill procedure, pointed at considerable pub-
lication bias. After adjustment for publication bias, the mean
effect size was reduced from g51.10 to g50.73 (95% CI: 0.51-
0.96; number of missed studies: 9). Egger’s test also pointed at
significant asymmetry of the funnel plot (p50.004; intercept:
2.42; 95% CI: 0.65-4.20).
In the subgroup analyses, excluding the extreme outliers,
we found that the risk of bias was significantly associated with
the effect size (p<0.001). The six comparisons with the lowest
risk of bias (no risk of bias for any of the four items of the
assessment tool) had an effect size of g50.51 (95% CI: 0.34-
0.69; NNT56.01) compared to g51.20 (95% CI: 0.84-1.56;
NNT52.29) in the studies with the highest risk of bias.
We also found that the type of control group was signifi-
cantly associated with the effect size, with care-as-usual con-
trol groups resulting in higher effect sizes than waiting list and
other control groups (p50.02).
None of the other subgroup analyses resulted in significant
differences between subgroups, and that included the region
(East Asia, Middle East and North Africa, South Asia, other),
the level of income of the country (high, upper middle, low/
lower middle), and whether or not the treatment was adapted
to the local situation.
We conducted a series of bivariate meta-regression analy-
ses. In these analyses, we found no indication that the effect
size was significantly associated with the GNI (coefficient:
0.00; 95% CI: 20.00 to 0.00; p50.56), the number of treatment
sessions (coefficient: 0.00; 95% CI: 20.04 to 0.04; p51.00), and
year of publication (coefficient: 0.00; 95% CI: 20.03 to 0.04;
p50.84).
Comparison between the effects of psychotherapy in
Western vs. non-Western countries
We considered the 32 comparisons from non-Western coun-
tries vs. the 291 comparisons from Western countries (Table 3;
extreme outliers with g>2.0 were excluded from these ana-
lyses). We found that the effect size in Western countries (g5
0.60; 95% CI: 0.55-0.64; I2559; 95% CI: 53-64; NNT54.99) was
significantly lower than in non-Western countries (p<0.001).
We also examined the effect sizes in the different regions
and found that they differed significant across regions (p<0.001),
with the lowest effect sizes in North America, Europe and Aus-
tralia, and the highest in East Asia, South Asia and the Middle
East and North Africa. We also found a significant difference
across countries with different incomes, with the highest ef-
fect sizes in low- and middle-income countries.
Table 3 Psychotherapies for adult depression in Western and non-Western countries compared with control conditions
N g 95% CI I2 95% CI p NNT
Western 291 0.60 0.55-0.64 59 53-64 <0.001 4.99
Non-Western 32 0.87 0.73-1.02 78 69-83 3.26
Region North America 165 0.67 0.59-0.74 61 53-67 <0.001 4.39
Europe 107 0.51 0.45-0.57 47 32-58 6.01
Australia 19 0.62 0.38-0.85 74 56-82 4.80
East Asia 17 0.83 0.64-1.02 77 61-84 3.44
Middle East and North Africa 6 1.17 0.69-1.65 74 18-87 2.35
South Asia 3 0.86 0.47-1.25 77 0-91 3.30
Other 6 0.73 0.30-1.16 85 64-91 3.98
Income level of country High 297 0.60 0.55-0.65 59 54-64 0.002 4.99
Upper middle 20 0.92 0.74-1.11 76 61-83 3.06
Low/lower middle 6 0.83 0.44-1.22 88 76-93 3.44
Income level of country High, Western 289 0.59 0.55-0.64 58 53-63 0.003 5.08
High, non-Western 8 0.86 0.48-1.23 71 24-84 3.30
Upper middlea 18 0.93 0.73-1.12 78 64-85 3.02
Low/lower middle 6 0.83 0.44-1.22 88 76-93 3.44
aTurkey was excluded from this analysis because it is a Western country but also an upper middle-income one
NNT – Numbers-needed-to-be-treated
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In addition, we conducted a separate subgroup analysis in
which we separated high-income countries into Western and
non-Western countries (Table 3). We found that the eight stud-
ies in high-income, non-Western countries resulted in an
effect size of g50.86 (95% CI: 0.48-1.23; NNT53.30; I2571;
95% CI: 24-84) compared to g50.59 in Western countries
(Table 2). A direct comparison between high-income countries
in Western and non-Western countries did not indicate a sig-
nificant difference (p50.17), but this may have been related to
the small number of studies from high-income non-Western
countries.
We conducted a series of multivariate meta-regression ana-
lyses with the effect size as dependent variable (Table 4). In
the first analysis, we included a dummy variable indicating
whether the study was conducted in a Western or non-West-
ern country, and also included other variables of the partici-
pants (a diagnosis of depression versus scoring above a cut-off
on a self-report scale; the target group), the therapies (type,
Table 4 Standardized regression coefficients of characteristics of studies on psychotherapies for depression in Western and non-
Western countries (full multivariate meta-regression analyses, excluding extreme outliers)
Coeff SE p Coeff SE p Coeff SE p
Western vs. non-Western countries 0.26 0.08 <0.001
Region North America Ref
Europe 20.02 0.06 0.83
Australia 0.08 0.10 0.44
East Asia 0.17 0.11 0.11
Middle East and North Africa 0.44 0.18 0.02
South Asia 0.44 0.20 0.03
Other 0.25 0.16 0.11
Income level of country High Ref
Low/lower middle 0.43 0.15 0.004
Upper middle 0.31 0.10 0.002
Diagnosis vs. cut-off 20.02 0.05 0.63 20.01 0.05 0.88 20.01 0.05 0.83
Target group Unselected adults Ref Ref Ref
Older adults 20.05 0.07 0.52 20.04 0.08 0.56 20.04 0.07 0.55
Women with PPD 20.04 0.08 0.65 20.04 0.08 0.61 20.04 0.08 0.58
General medical disease 0.04 0.07 0.57 0.04 0.07 0.60 0.04 0.07 0.53
Other 0.05 0.07 0.45 0.03 0.07 0.64 0.06 0.07 0.38
Type of therapy CBT Ref Ref Ref
IPT 20.08 0.09 0.39 20.07 0.09 0.44 20.09 0.09 0.33
PST 20.03 0.10 0.75 20.02 0.10 0.84 20.03 0.09 0.73
Supportive 0.03 0.11 0.81 0.05 0.11 0.67 0.05 0.11 0.65
Other 0.02 0.06 0.75 0.03 0.06 0.64 0.02 0.06 0.72
Format of therapy Individual Ref Ref Ref
Group 20.10 0.06 0.08 20.10 0.06 0.07 20.12 0.06 0.03
Guided self-help 0.05 0.07 0.53 0.04 0.08 0.57 0.03 0.07 0.67
Other/mixed 20.17 0.10 0.09 20.15 0.10 0.13 20.18 0.10 0.07
Number of sessions (continuous) 20.00 0.01 0.68 0.00 0.01 0.54 0.00 0.01 0.65
Risk of bias (continuous) 20.12 0.02 <0.001 20.12 0.02 <0.001 20.12 0.02 <0.001
Control group Waiting list Ref Ref Ref
Care as usual 20.09 0.06 0.14 20.10 0.06 0.13 20.11 0.06 0.08
Other 20.21 0.07 <0.01 20.23 0.07 <0.001 20.23 0.07 <0.001
Intercept 1.01 0.10 <0.001 1.00 0.10 <0.001 1.03 0.10 <0.001
R2 analog 0.36 0.36 0.38
Coeff – regression coefficient, Ref – reference group, PPD – post-partum depression, CBT – cognitive behavior therapy, IPT – interpersonal psychotherapy, PST –
problem solving therapy
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treatment format, number of sessions) and characteristics of
the studies (type of control group and risk of bias). Whether the
study was conducted in a Western or non-Western country
remained a significant predictor of the effect size after adjust-
ing for all other characteristics of the participants, interven-
tions and studies (p<0.001).
In the second meta-regression analysis we used the same
predictors, except that the dummy variable indicating that the
study was conducted in a Western vs. a non-Western country
was removed, and instead we added the variable indicating
the region where the study was conducted. We found that
studies conducted in the Middle East and North Africa, and in
South Asia had significantly higher effect sizes than the refer-
ence group (studies from the United States).
In the third meta-regression analysis, we included the
income of the country as predictor, and we found that both
studies conducted in upper middle- (p50.002) and in low/
lower middle-income countries (p50.004) had significantly
higher effect sizes than those in high-income countries, while
adjusting for all other variables.
We did not include the dummies indicating Western versus
non-Western countries, the regions and the income level in
one analysis, because the overlap across these variables was
considered too large.
To avoid overfit of the meta-regression models, we repeated
the above three meta-regression analyses with a (manual) step-
wise backward elimination of the least significant predictor
until only significant predictors remained in the model. The
results of these parsimonious analyses are presented in Table 5.
As can be seen, in all three models, risk of bias and type of con-
trol group remained significant, as well as the dummies indi-
cating Western vs. non-Western countries, the regions and the
income level.
DISCUSSION
Our study documents that psychotherapies for depression
that have been developed in Western countries are also effec-
tive in non-Western countries. We even found indications that
these therapies may be more effective in non-Western than in
Western countries. This finding remained significant in multi-
variate meta-regression analyses in which we controlled for
characteristics of the participants, the interventions and the
studies.
We classified these studies in different ways, one in which
we simply differentiated between Western and non-Western
countries, one in which we categorized the countries into the
major regions of the world according to the World Bank, and
one in which we classified the countries according to their
income (high, upper middle and low/lower middle). We found
that the studies in non-Western countries had better outcomes
than those from Western countries; that the effect sizes were
Table 5 Standardized regression coefficients of characteristics of studies on psychotherapies for depression in Western and non-
Western countries (parsimonious multivariate meta-regression analyses)
Coeff SE p Coeff SE p Coeff SE p
Western vs. non-Western countries 0.23 0.07 <0.001
Region North America Ref
Europe 20.01 0.06 0.91
Australia 0.08 0.10 0.42
East Asia 0.13 0.10 0.21
Middle East and North Africa 0.43 0.17 0.01
South Asia 0.40 0.19 0.04
Other 0.22 0.15 0.15
Income level of country High Ref
Low/lower middle 0.36 0.14 0.01
Upper middle 0.24 0.09 0.01
Risk of bias (continuous) 20.10 0.02 <0.001 20.10 0.02 <0.001 20.11 0.02 <0.001
Control group Waiting list Ref Ref Ref
Care as usual 20.12 0.05 0.02 20.12 0.05 0.02 20.13 0.05 0.02
Other 20.23 0.06 <0.001 20.25 0.06 <0.001 20.25 0.06 <0.001
Intercept 0.98 0.05 <0.001 0.98 0.06 <0.001 0.99 0.05 <0.001
R2 analog 0.37 0.37 0.38
Coeff – regression coefficient, Ref – reference group
World Psychiatry 17:1 - February 2018 99
especially high in the Middle East and North-Africa, and in
South Asia (although the lack of statistical significance for
other regions may be caused by lack of power) and that studies
in upper middle- and low/lower middle-income countries re-
sulted in significantly higher effect sizes than studies in high-
income countries.
It is not clear why the studies in non-Western countries had
better outcomes. It is possible that these therapies simply
work better in (some) non-Western countries, but it is not
clear why that would be the case. Another explanation could
be that most studies in non-Western countries had care-as-
usual control groups, and that care-as-usual in these cases
simply means to get no treatment at all, while in Western
countries care-as-usual implies that patients have access to
several treatments, like regular care provided by general prac-
titioners or specialized mental health services. Another expla-
nation could be that the quality of the studies conducted in
non-Western countries was not optimal. Risk of bias was low
in only 6 of the 32 included comparisons, and these studies
with low risk of bias had considerably lower effect sizes than
those with higher risk, very comparable to the ones found in
Western countries.
We did not find indications that a specific adaptation of the
treatment to the context where the therapy was conducted
was associated with better outcomes. This finding should be
considered with caution, because the description of the inter-
vention was very brief in most papers, so that it cannot be
excluded that the interventions were still adapted although
this was not mentioned in the paper.
These findings do suggest that psychotherapies developed
in Western countries can be implemented in non-Western
countries when sufficient resources are available and without
culturally adapting them. It has been argued recently that an
investment in mental health care in low- and middle-income
countries has considerable economic support5. Because we
found no indication that the effects are associated with the
treatment format, it would be possible to introduce low inten-
sity interventions as a first line treatment, because these are
easier and cheaper to implement than high intensity ones.
This study has several limitations that have to be taken into
account when interpreting the results. One important limita-
tion is that we may have missed studies because our searches
mainly focused on Western databases, while studies published
in other languages were not directly accessible. That implies
that our results may be distorted because of bias in the selec-
tion of studies. Another limitation is that the quality of most of
the included studies was not optimal, and only a handful of
them had a high quality. Furthermore, these high-quality stud-
ies found considerably smaller effect sizes than the others, sug-
gesting that the true effects are probably smaller than we found.
However, after adjustment for study quality, studies in non-
Western countries were still had better outcomes than those in
Western countries. Another limitation is that most studies in
non-Western countries were conducted in a selected sample of
countries in Asia, and only few in Africa and Latin America.
Despite these limitations, this study suggests that psycho-
therapies developed in Western countries may or not be more
effective in non-Western countries, but are probably no less
effective and can therefore also be used in these latter coun-
tries, regardless of their income level.
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